Advertisement

Satori Pharmaceuticals Inc., a Cambridge-based developer of drugs for neurodegenerative disorders, has raised $7 million in a new round of financing that is targeting $20 million, according to federal documents.

If the full $20 million is raised, the latest financing brings Satori, which was founded in 2004, to a total of almost $46 million in funding, including its $22 million Series A round in 2007.

SOURCE

Advertisement
Advertisement